Myelofibrosis - 44 Studies Found
Completed |
: A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis : Myelofibrosis : 2008-07-17 : Drug: SAR302503 (TG101348) orally administered, once a day |
Recruiting |
: Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis : Myelofibrosis : 2016-08-26 |
Active, not recruiting |
: Lenalidomide for Patients With Myelofibrosis (MF) : Myelofibrosis : 2006-07-14 :
|
Active, not recruiting |
: Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis : Myelofibrosis : 2012-12-24 : Drug: Peginterferon alfa-2a 50 mcg subcutaneous injection once per week |
Active, not recruiting |
: JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis : Myelofibrosis : 2012-12-21 : Drug: Ruxolotinib Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT f |
Active, not recruiting |
: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) : Myelofibrosis : 2012-09-14 :
|
Recruiting |
: Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis : Myelofibrosis : 2016-09-30 : Other: Hematopoietic Stem Cell Transplant This observational study will compare outcomes of prospectivel |
Completed |
: Ph II Study of Azacitidine in Myelofibrosis : Myelofibrosis : 2007-12-06 : Drug: Azacitidine 75 mg/m^2 subcutaneous daily for 7 days (every 4 week cycle) |
Completed |
: Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis : Myelofibrosis : 2010-06-22 : Drug: APLIDIN (plitidepsin) Aplidin® (plitidepsin) ly |
Completed |
: A Phase II Study of CC-5013 in Myelofibrosis : Myelofibrosis : 2004-07-12 : Drug: CC-5013 10 mg orally (2 capsules) daily Other |